| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 3434 | 2016 |
| Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised … B Nordlinger, H Sorbye, B Glimelius, GJ Poston, PM Schlag, P Rougier, ... The Lancet 371 (9617), 1007-1016, 2008 | 2324 | 2008 |
| Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study J Lammer, K Malagari, T Vogl, F Pilleul, A Denys, A Watkinson, M Pitton, ... Cardiovascular and interventional radiology 33, 41-52, 2010 | 1800 | 2010 |
| Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised … B Nordlinger, H Sorbye, B Glimelius, GJ Poston, PM Schlag, P Rougier, ... The lancet oncology 14 (12), 1208-1215, 2013 | 1282 | 2013 |
| Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial G Folprecht, T Gruenberger, WO Bechstein, HR Raab, F Lordick, ... The lancet oncology 11 (1), 38-47, 2010 | 1219 | 2010 |
| Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JW Valle, I Borbath, SA Khan, F Huguet, T Gruenberger, D Arnold Annals of Oncology 27, v28-v37, 2016 | 654 | 2016 |
| Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer B Gruenberger, D Tamandl, J Schueller, W Scheithauer, C Zielinski, ... Journal of clinical oncology 26 (11), 1830-1835, 2008 | 539 | 2008 |
| Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel B Nordlinger, E Van Cutsem, T Gruenberger, B Glimelius, G Poston, ... Annals of Oncology 20 (6), 985-992, 2009 | 464 | 2009 |
| Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial T Gruenberger, J Bridgewater, I Chau, PG Alfonso, M Rivoire, S Mudan, ... Annals of Oncology 26 (4), 702-708, 2015 | 371 | 2015 |
| Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases … B Nordlinger, E Van Cutsem, P Rougier, CH Köhne, M Ychou, A Sobrero, ... European journal of cancer 43 (14), 2037-2045, 2007 | 365 | 2007 |
| Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study B Gruenberger, J Schueller, U Heubrandtner, F Wrba, D Tamandl, ... The lancet oncology 11 (12), 1142-1148, 2010 | 315 | 2010 |
| Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study) G Folprecht, T Gruenberger, W Bechstein, HR Raab, J Weitz, F Lordick, ... Annals of oncology 25 (5), 1018-1025, 2014 | 286 | 2014 |
| Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer … E Tanis, B Nordlinger, M Mauer, H Sorbye, F Van Coevorden, ... European journal of cancer 50 (5), 912-919, 2014 | 262 | 2014 |
| Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis C Pulitanò, M Bodingbauer, L Aldrighetti, MC De Jong, F Castillo, ... Annals of surgical oncology 18, 1380-1388, 2011 | 201 | 2011 |
| Urgent need for a new staging system in advanced colorectal cancer GJ Poston, J Figueras, F Giuliante, G Nuzzo, AF Sobrero, JF Gigot, ... Journal of clinical oncology 26 (29), 4828-4833, 2008 | 200 | 2008 |
| Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases M Klinger, S Eipeldauer, S Hacker, B Herberger, D Tamandl, ... European Journal of Surgical Oncology (EJSO) 35 (5), 515-520, 2009 | 199 | 2009 |
| Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer C Cremolini, C Antoniotti, A Stein, J Bendell, T Gruenberger, D Rossini, ... Journal of Clinical Oncology 38 (28), 3314-3324, 2020 | 193 | 2020 |
| HER 2/neu protein expression in colorectal cancer B Schuell, T Gruenberger, W Scheithauer, C Zielinski, F Wrba BMC cancer 6, 1-5, 2006 | 193 | 2006 |
| Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma D Tamandl, B Herberger, B Gruenberger, H Puhalla, M Klinger, ... Annals of surgical oncology 15, 2787-2794, 2008 | 190 | 2008 |
| Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial GV Kornek, B Schuell, F Laengle, T Gruenberger, M Penz, K Karall, ... Annals of oncology 15 (3), 478-483, 2004 | 163 | 2004 |
Graeme PostonUniversity of LiverpoolVerified email at blueyonder.co.uk
